Flagship Pioneering and Amazon Web Services (AWS) have jointly decided to work closely through a strategic collaboration to bring about quick changes in the fields of drug discovery and life sciences. To become a robust platform of biotechnology companies, the collaboration intricately combines the use of intelligent cloud infrastructure with advanced artificial intelligence tools, thereby enabling quicker and more efficient scientific discoveries.
AWS has been named as the primary cloud provider for Flagship Pioneering under the new deal, helping its run of businesses continue to develop and expand digitally native and AI-native platforms. Via the use of scalable computing and data-driven insights, these platforms are anticipated to help separate human health, sustainability, and other scientific areas by their innovative features.
Through this partnership, early-stage companies within Flagship’s portfolio will have access to credits, technical expertise, and a full range of AI and machine learning services from AWS. In addition, there will be access to go-to-market assistance from AWS, which will help these organizations leverage a broader network of customers. This will help in reducing the time it takes for these organizations to go from research and discovery into application and real-world implementation.
Flagship’s internal teams will also benefit from specialized technical guidance. This will help them in developing the potential for creating, developing, and growing innovative companies that have a strong foundation in digital and AI technologies.
“AI is no longer a theoretical tool in the life sciences it’s a catalyst that’s fundamentally accelerating how we understand nature and generate breakthroughs,” said Avak Kahvejian, President of Flagship Labs and General Partner, Flagship Pioneering. “This collaboration with AWS will enable Flagship Labs and our companies to access more technological capabilities to push scientific boundaries further and faster.”
Also Read: Tempus and Daiichi Sankyo Partner to Accelerate AI-Driven Biomarker Discovery in Oncology
“Life science innovation increasingly depends on the ability to compute at scale, experiment rapidly, and move seamlessly from discovery to deployment,” said Jason Bennett, Vice President and Global Head of Startups at AWS. “Through this collaboration with Flagship Pioneering, we’re providing reliable, secure, and scalable infrastructure and AI capabilities that enable startups rapid experimentation and scaling of breakthrough discoveries, ultimately helping to transform how we approach everything from drug discovery to climate change.”
The collaboration builds upon a strong history of successful engagements between AWS and Flagship-founded companies, including Moderna and Lila Sciences. These earlier initiatives have demonstrated how cloud computing and AI can accelerate the development of transformative therapies and scientific platforms.
Flagship Pioneering, which was founded back in 2000, has been very influential in shaping the life sciences industry by launching and growing over 100 organizations.
Currently, with over 40 ventures and billions of dollars under management, the company is committed to building innovations that are based on platforms and have the potential to create several products across various industries. This partnership is an example of how biotechnology and high-end computing are becoming increasingly intertwined. Flagship and AWS are looking to unlock new possibilities and accelerate drug discovery while reducing the time to market and tackling some of the world’s most pressing issues.
